TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kazia Therapeutics ( (KZIA) ) has shared an update.
On October 7, 2025, Kazia Therapeutics announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program, featuring the lead compound NDL2. This innovative cancer immunotherapy targets advanced breast cancer and non-small cell lung cancer, aiming to overcome resistance to current PD-1/PD-L1 therapies. The agreement positions Kazia at the forefront of next-generation immuno-oncology, with plans to integrate NDL2 with its existing assets, potentially enhancing its market position and offering new therapeutic options for stakeholders.
The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. The company is known for its lead program, paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat various forms of cancer. Kazia has been involved in multiple clinical trials for paxalisib and is also developing EVT801, a small molecule inhibitor of VEGFR3, showcasing its commitment to advancing cancer treatment.
Average Trading Volume: 307,151
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.22M
For detailed information about KZIA stock, go to TipRanks’ Stock Analysis page.